The Great GIP Paradox

These sources collectively discuss the *glucose-dependent insulinotropic polypeptide (GIP)* and *glucagon-like peptide-1 (GLP-1)* hormones and their roles in metabolism, particularly concerning obesity and type 2 diabetes. Several texts explore *GIP receptor antagonism* as a potential therapeutic strategy for weight loss, often in combination with *GLP-1 receptor agonism**, citing both genetic evidence and preclinical and clinical trial data for such approaches. Specifically, **Maridebart cafraglutide (MariTide)**, a dual GLP-1 receptor agonist and GIP receptor antagonist, is highlighted as a promising monthly treatment showing significant weight and glycemic reductions. Other sources illuminate the **physiological similarities and differences* between GIP and GLP-1, detailing their individual effects on insulin secretion, fat deposition, bone metabolism, and appetite control, while some texts also touch upon the development of *multi-target drug compounds* that go beyond GLP-1 and GIP to include additional hormones like PYY for even greater weight loss efficacy. Finally, some articles present detailed *pharmacological characterizations* of GIP receptor variants and the signaling profiles of endogenous agonists and therapeutic drugs like tirzepatide.